$CATX News
Last published 2d ago
- 2d agoCATXPerspective Therapeutics, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 8.01 Item 9.01
- 2d agoCATXPerspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2026 ResultsGlobeNewswireUpdated interim data from the Phase 1/2a bamzireotide navoxetan (VMT-α-NET) presentations continue to support an emerging therapeutic window and potential to achieve a best-in-class profile in NETsMeaningful antitumor
- 2d agoCATXPerspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2026 ResultsGlobeNewswireSEATTLE, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced systemic treatments for cancers, today provided a business update and announced results for the quarter ended September 30, 2026.
- 5d agoCATXPerspective Therapeutics Presents Promising [212Pb]Lapemelanotide Zapixetar (VMT01) Monotherapy Data from a Phase 1/2a Study in Heavily Pretreated Advanced Melanoma Patients at SITC 2026GlobeNewswireMeaningful antitumor activity observed at the 3.0 mCi monotherapy dose with 75% disease control rate and durable disease stabilization; one of two confirmed responders remains on study ~40 weeks after the first
- 5d agoCATXPerspective Therapeutics Presents Promising [212Pb]Lapemelanotide Zapixetar (VMT01) Monotherapy Data from a Phase 1/2a Study in Heavily Pretreated Advanced Melanoma Patients at SITC 2026GlobeNewswireMeaningful antitumor activity observed at the 3.0 mCi monotherapy dose with 75% disease control rate and durable disease stabilization; one of two...
- 6d agoCATXPerspective Therapeutics Presents Encouraging Incremental Data and Analyses from Phase 1/2a Trial of [212Pb]Bamzireotide Navoxetan (VMT-α-NET) in Advanced SSTR2 Expressing NETsGlobeNewswireAdditional analyses presented at NANETS 2026 Multidisciplinary NET Medical Symposium support prior findings of durable ongoing disease control and...
- 6d agoCATXPerspective Therapeutics Presents Encouraging Incremental Data and Analyses from Phase 1/2a Trial of [212Pb]Bamzireotide Navoxetan (VMT-α-NET) in Advanced SSTR2 Expressing NETsGlobeNewswireAdditional analyses presented at NANETS 2026 Multidisciplinary NET Medical Symposium support prior findings of durable ongoing disease control and encouraging responses in all three cohorts across multiple patient
- 2w agoCATXPerspective Therapeutics investor call on VMT-α-NET data at ESMO Congress 2026 - PERSPECTIVE THERAPEUTICS INCEarnings Call TranscriptsGreetings. Welcome to the Perspective Therapeutics Investor Call on VMT AlphaNet data at ESMO Congress 2026. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal
- 2w agoCATXPerspective’s [212Pb]Bamzireotide Navoxetan (VMT-α-NET) Demonstrates Encouraging Safety, Durable Disease Control, and Robust Tumor Response Across Multiple Dose Cohorts in Phase 1/2a Trial in Advanced SSTR2-Expressing NETsGlobeNewswireResults presented at ESMO show a promising therapeutic index for [212Pb]VMT-α-NETDurable disease control in all three cohorts and 72% PFS at 18 months across all patients who received at least one treatmentRobust
- 1mo agoCATXPerspective Therapeutics Granted Fast Track Designation for [212Pb]PSV359 for the Treatment of Adult Patients with Locally Advanced Unresectable and/or Metastatic FAP-Positive Solitary Fibrous TumorsGlobeNewswireSEATTLE, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us," and "our") (NYSE:CATX), a radiopharmaceutical development
- 1mo agoCATXPerspective Therapeutics Announces Acceptance of [212Pb]VMT-α-NET Data for Presentation at the NANETS 2026 Multidisciplinary NET Medical SymposiumGlobeNewswireSEATTLE, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us," and "our") (NYSE:CATX), a radiopharmaceutical development
- 1mo agoCATXPerspective Therapeutics - 1773753 - PERSPECTIVE THERAPEUTICS INCEarnings Call TranscriptsGood morning, everyone. I'm very happy to be here with my friend, Chase Spohr, the CEO of Perspective Therapeutics. Really happy you're here on the third day of the Morgan Stanley Healthcare Conference. So thank you for
- 1mo agoCATXMRKPerspective Therapeutics Announces Clinical Collaboration and Supply Agreement with Merck to Evaluate [212Pb]PSV359 in Combination with Keytruda® (Pembrolizumab) in FAP-α Positive Solid TumorsGlobeNewswireSEATTLE, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us," and "our") (NYSE:CATX), a radiopharmaceutical development
- 3mo agoCATXPerspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2026 ResultsGlobeNewswireAdvancing VMT-α-NET toward a Phase 3 study in neuroendocrine tumors, subject to regulatory alignment: regulatory engagement ongoing; clinical site activation targeted around year-end 2026 subject to regulatory feedback;
- 3mo agoCATXPerspective Therapeutics to Provide Business Highlights and Report Second Quarter 2026 Financial ResultsGlobeNewswireSEATTLE, July 31, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical development company pioneering advanced treatments for
- 3mo agoCATXPerspective Therapeutics Receives European Orphan Medicinal Product Designation for [212Pb]VMT-α-NET in GEP-NETsGlobeNewswireEuropean orphan medicinal product designation granted for [²¹²Pb]VMT-α-NET for the treatment of GEP-NETs[²¹²Pb]VMT-α-NET is being evaluated in an ongoing Phase 1/2a study in patients with SSTR2-positive neuroendocrine
- 3mo agoCATXPerspective Therapeutics Announces Acceptance of VMT-α-NET Data for Oral Presentation at the ESMO Congress 2026GlobeNewswireSEATTLE, July 17, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us," and "our") (NYSE:CATX), a radiopharmaceutical development
- 4mo agoCATXPerspective Therapeutics Appoints Paul Lyne, Ph.D., as Chief Science Officer; Co-Founder Michael K. Schultz, Ph.D., Transitions to Senior Scientific AdvisorGlobeNewswireSEATTLE, July 08, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us," and "our") (NYSE:CATX), a radiopharmaceutical development
- 5mo agoCATXPerspective Therapeutics Expands Therapeutic Focus Areas; First Patient Dosed with [212Pb]VMT-α-NET in the Meningioma Cohort of a Phase 1/2a StudyGlobeNewswireSEATTLE, June 03, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us," and "our") (NYSE:CATX), a radiopharmaceutical development company pioneering advanced treatments for
- 5mo agoCATXPerspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in MelanomaGlobeNewswireOne new responder observed in the [212Pb]VMT01 3.0 mCi monotherapy cohort for a total of two confirmed responses out of seven (29%) treated in this cohort of the Phase 1/2a study in heavily pre-treated melanoma; further
- 5mo agoCATXPerspective Therapeutics Announces First Patients Dosed in New Cohorts of Two Ongoing Phase 1/2a StudiesGlobeNewswireSEATTLE, May 18, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us," and "our") (NYSE:CATX), a radiopharmaceutical development company pioneering advanced treatments for
- 6mo agoCATX2026 GLOBAL HEALTHCARE CONFERENCE - PERSPECTIVE THERAPEUTICS INCEarnings Call TranscriptsAll right. Great. Okay. Let's get going. Thanks, everyone, for joining this session with Perspective Therapeutics. My name is Alex Stranahan. I'm Senior Biotech Analyst at Bank of America covering Perspectiv. And I'm ple
- 6mo agoCATXPerspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2026 ResultsGlobeNewswireDifferentiated ²¹²Pb radiopharmaceutical platform designed to optimize tumor killing, safety, patient convenience and supply scalabilityThree clinical-stage oncology programs advancing across neuroendocrine tumors,
- 6mo agoCATXPerspective Therapeutics to Provide Several Upcoming Corporate UpdatesGlobeNewswireSEATTLE, April 24, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout
- 6mo agoCATXPerspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in Its Ongoing Phase 1/2a Clinical Trial at the 2026 AACR Annual MeetingGlobeNewswireUpdated interim results with an additional ~12 weeks of follow-up since prior update at ASCO-GI in January 2026 and ~25 weeks since ESMO in October 2025Safety update presented on all 64 patients who received at least one
- 7mo agoCATXPerspective Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswireSEATTLE, April 02, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout
- 8mo agoCATXPerspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2025 ResultsGlobeNewswireLead program VMT-α-NET in neuroendocrine tumors continues to demonstrate a favorable tolerability profile with durable disease control and deepening of tumor response with longer follow-up, as reported at ASCO-GI
- 8mo agoONCYNVCRCATXIBRX+1New Treatment Modalities Are Reaching Cancers That Resisted Everything ElsePR NewswireEquity-Insider.com News Commentary – More than 2,100 oncology clinical trials were initiated globally in 2024, with targeted therapies representing...
- 8mo agoONCYNVCRCATXIBRX+1New Treatment Modalities Are Reaching Cancers That Resisted Everything ElsePR NewswireEquity-Insider.com News Commentary – More than 2,100 oncology clinical trials were initiated globally in 2024, with targeted therapies representing...
- 8mo agoCATXPerspective Therapeutics to Provide Business Highlights and Report Full Year 2025 Financial ResultsGlobeNewswireSEATTLE, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical development company pioneering advanced treatments for
- 9mo agoCATXPerspective Therapeutics Announces Pricing of $175 Million Underwritten Offering of Common Stock and Pre-Funded WarrantsGlobeNewswireSEATTLE, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company that is pioneering advanced treatments for cancers throughout the
- 9mo agoONCYPFEVSTMCATX+1$668B Oncology Surge: 5 Platforms Cracking the Code on GI TumorsPR NewswireThe global oncology sector is rocketing toward $668 billion in 2034[1], partly fueled by a massive structural pivot toward gastrointestinal cancers...
- 10mo agoCATXPerspective Therapeutics Provides Business Updates and Strategic Priorities Ahead of Presentation at 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswireContinued strong patient recruitment in neuroendocrine tumors for lead program VMT-α-NET sets the stage for submissions of robust clinical data package for presentation to more medical conferences in 2026, as well as
- 10mo agoCATXPerspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial at the 2026 ASCO Gastrointestinal Cancers SymposiumGlobeNewswireUpdated interim results with an additional ~13 weeks of follow-up since the prior update[212Pb]VMT-α-NET continues to be well-tolerated Updated efficacy analysis suggests durable disease control and deepening of tumor
- 10mo agoCATXPerspective Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswireSEATTLE, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical development company pioneering advanced treatments for
- 11mo agoCATXPerspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ASCO Gastrointestinal Cancers SymposiumGlobeNewswireSEATTLE, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout
- 11mo agoCATXPerspective Therapeutics to Participate in Upcoming December ConferencesGlobeNewswireSEATTLE, Nov. 20, 2025 (GLOBE NEWSWIRE) -- November 20, 2025 – Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical development company pioneering advanced
- 1y agoCATXPerspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2025 ResultsGlobeNewswireUpdated interim results from the Company's [212Pb]VMT-α-NET Phase 1/2a study supporting the therapy's compelling overall clinical profile at the 5 mCi dose were presented at the ESMO Congress 2025, NANETS and Triple
- 1y agoCATXPerspective Therapeutics to Participate in Upcoming November ConferencesGlobeNewswireSEATTLE, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical development company pioneering advanced treatments for
- 1y agoCATXPerspective Therapeutics to Provide Business Highlights and Report Third Quarter 2025 Financial ResultsGlobeNewswireSEATTLE, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical development company pioneering advanced treatments for
- 1y agoCATXPerspective Therapeutics Presents Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the ESMO Congress 2025GlobeNewswireUpdated interim results with an additional ~19 weeks of follow-up since the prior update [212Pb]VMT-α-NET continues to be well-tolerated Objective Response Rate of 44% (7 of 16 patients) in Cohort 2 with SSTR2 expression
- 1y agoCATXPerspective Therapeutics Announces First Patient Dosed with PSV359 in the Second Cohort of a Phase 1/2a Study in Patients with FAP-α Positive Solid TumorsGlobeNewswireSEATTLE, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company that is pioneering advanced treatments for cancers
- 1y agoCATXPerspective Therapeutics Progresses Dose Finding for [212Pb]VMT01 in Combination with Nivolumab in its Ongoing Phase 1/2a Study of MC1R-Positive Metastatic MelanomaGlobeNewswireFirst patient dosed with [212Pb]VMT01 3.0 mCi in combination with nivolumab[212Pb]VMT01 3.0 mCi single agent dose Cohort re-opened SEATTLE, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics,
- 1y agoCATXPerspective Therapeutics Appoints Biotech Veteran Joel Sendek as Chief Financial OfficerGlobeNewswireSEATTLE, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company pioneering advanced treatments for cancers
- 1y agoCATXPerspective Therapeutics Appoints Maya Martinez-Davis to Board of DirectorsGlobeNewswireSEATTLE, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company pioneering advanced treatments for cancers
- 1y agoCATXPerspective Therapeutics to Participate in Upcoming September ConferencesGlobeNewswireSEATTLE, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company pioneering advanced treatments for cancers
- 1y agoCATXPerspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2025 ResultsGlobeNewswire[212Pb]VMT-α-NET study update presented at the 2025 ASCO Annual Meeting, based on updated interim results from a Phase 1/2a study in neuroendocrine tumors. As of the April 30, 2025 data cut-off date: Four of the initial
- 1y agoCATXPerspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ESMO Congress 2025GlobeNewswireSEATTLE, July 24, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body,
- 1y agoONCYCUEVSTMALLO+1High‑Growth Oncology Market Projected For US$900bn in Revenue Despite Policy HeadwindsPR NewswireUSA News Group News Commentary – Cancer diagnoses are climbing fastest among younger women, sparking alarm that looming cuts to U.S. research budgets ...
- 1y agoCATXPerspective Therapeutics to Provide Business Highlights and Report Second Quarter 2025 Financial ResultsGlobeNewswireSEATTLE, July 15, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body,